profit from every $100 of sales.
$0$100
Organogenesis Holdings
$0.97-8.10% today
-85.1% in 1 year
1-year low $0.761-year high $6.48
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $3.38 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Organogenesis Holdings sold, what it kept, and what it did with the cash.
Sales went from $451 million in 2022 to $563 million in 2025, with $37.0 million of profit last year.
SalesProfit
Organogenesis Holdings vs. similar companies
Organogenesis Holdings grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Organogenesis Holdings | 3.4× · Cheap | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Organogenesis Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 451 | 433 | 482 | 563 | |
| 346 | 327 | 366 | 426 | |
| 22 | 13 | 22 | 56 | |
| 40 | 36 | 24 | 83 | |
| 16 | 5 | 1 | 37 | |
| 0.12 | 0.04 | -0.01 | 0.15 | |
| 76.7% | 75.4% | 76.0% | 75.6% | |
| 4.9% | 2.9% | 4.5% | 9.9% | |
| 3.4% | 1.1% | 0.2% | 6.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 449 | 460 | 498 | 599 |
| Cash | 102 | 104 | 136 | 94 |
| Total debt | 124 | 119 | 43 | 82 |
| Total liabilities | 184 | 181 | 113 | 165 |
| 266 | 279 | 385 | 434 | |
| 132 | 133 | 132 | 130 | |
| 4.5% | 2.5% | -0.2% | 8.6% | |
| 5.8% | 1.8% | 0.2% | 8.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 25 | 31 | 14 | -10 | |
| 34 | 24 | 10 | 14 | |
| -9 | 7 | 4 | -24 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 25 | 0 | |
| 7 | 9 | 11 | 13 |
Valuation
- 3.4×
- –
- 0.44
- 0.8×
- 0.2×
- –
- 1.4×
- -19.5%
- 29.6%
- 0.0%
Profitability
- 75.6%
- 9.9%
- 6.6%
- 7.9%
- -0.1%
- 7.4%
- -0.1%
- -0.1%
- 1.9%
- 9.5%
Growth
- +7.7%
- +7.7%
- −685.7%
- –
- −0.3%
Financial health
- -0.5×
- 0.19
- 13.6%
- 12.8×
- 3.53
- 3.16
- 0.99
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 952
Top 48%of 883
Top 1%of 576
Bottom 38%of 870
Bottom 4%of 985
What analysts expect
- Average price target
- $9.00
- Range
- $9.00 – $9.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.37 | -0.29 | −27.6% |
| Feb 26, 2026 | 0.31 | 0.22 | +44.2% |
| Nov 6, 2025 | 0.18 | 0.21 | −14.3% |
| Aug 7, 2025 | -0.09 | 0.07 | −228.6% |
| May 8, 2025 | -0.13 | 0.04 | −425.0% |
| Feb 27, 2025 | 0.04 | -0.03 | +233.3% |
| Nov 12, 2024 | 0.09 | 0.01 | +700.0% |
| Aug 8, 2024 | -0.13 | -0.02 | −550.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
55No pass
Benjamin Graham
96Pass
Philip Fisher
53No pass
Peter Lynch
61Pass
Joel Greenblatt
60Pass
Charlie Munger
46No pass
Terry Smith
35No pass
Questions about Organogenesis Holdings
Is Organogenesis Holdings a good stock to buy?
A business with weak numbers, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Organogenesis Holdings AI analysis
What does Organogenesis Holdings do?
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. It is in Drug Manufacturers - Specialty & Generic.
Does Organogenesis Holdings pay a dividend?
No. Organogenesis Holdings does not pay a dividend at the moment.
Is Organogenesis Holdings stock halal?
No. Organogenesis Holdings does not pass our halal screen: its debt is 66% of its market value, at or above the 33% limit. How we check
How has Organogenesis Holdings stock done over the past year?
Down 85.1% over the past twelve months, to $0.97. It traded between $0.76 and $6.48 and is 85.1% below its high.
Who are Organogenesis Holdings's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Organogenesis Holdings's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.